Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2018
Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström MacroglobulinemiaNa Li, Michael A Lopez, Maria Linares, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2021
Functional Impact of Genomic Complexity on the Transcriptome of Multiple MyelomaBachisio Ziccheddu, Matteo C Da Vià, Marta Lionetti, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 9, 2018
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune ProfilingSarah A Holstein, J Christine Ye, Alan Howard, et al.
Blood|May 24, 2014
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 studySara Bringhen, Maria Teresa Petrucci, Alessandra Larocca, et al.
Haematologica|August 30, 2023
What is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome?Francesco Autore, Stefania Bramanti, Federica Lessi, et al.
Cancer|December 19, 2018
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysisManuela Gambella, Paola Omedé, Stefano Spada, et al.
Blood|June 19, 2013
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated resultsFrancesca Gay, Valeria Magarotto, Claudia Crippa, et al.
Haematologica|December 9, 2017
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectivesFrancesca Gay, Monika Engelhardt, Evangelos Terpos, et al.
Oncotarget|October 26, 2016
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysisStefania Oliva, Manuela Gambella, Milena Gilestro, et al.
Hematological Oncology|June 2, 2024
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosisClaudia Bellofiore, Pietro Benvenuti, Roberto Mina, et al.
Pageof 6